Novo Nordisk acquisition of Neotope Neuroscience
We advised Novo Nordisk on the acquisition
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Lydall $1.3 billion acquisition by Unifrax
We are advising Lydall on the transaction
Virgin Group Acquisition Corp. II $350 million IPO
We advised Virgin Group Acquisition Corp. II, a SPAC, on its IPO and NYSE listing
Evernorth acquisition of MDLIVE
We are advising MDLIVE on the transaction
Technip Energies completes its spinoff from TechnipFMC
We advised Technip Energies on its spinoff
23andMe $3.5 billion merger with Virgin Group’s VG Acquisition
We are advising a SPAC on its merger with 23andMe
cxLoyalty Group Holdings sale of Global Loyalty division to JPMorgan Chase
Davis Polk is advising cxLoyalty Group Holdings, Inc. in connection with its definitive agreement to sell its Global Loyalty division to JPMorgan Chase & Co. The deal includes cxLoyalty…
Novo Nordisk acquisition of Emisphere Technologies
Davis Polk is advising Novo Nordisk A/S on its $1.8 billion acquisition of Emisphere Technologies Inc. and related Eligen SNAC royalty stream obligations owed to MHR Fund Management LLC,…
VG Acquisition $480 million IPO
Davis Polk advised VG Acquisition Corp. on its $480 million initial public offering of 48,000,000 units. Each unit had an initial offering price of $10 and consists of one Class A ordinary…
Novo Nordisk $725 million acquisition of Corvidia Therapeutics
Davis Polk is advising Novo Nordisk A/S on its acquisition of Corvidia Therapeutics Inc. for an upfront payment of $725 million in cash. Total payments to Corvidia Therapeutics shareholders…